GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper) is a naturally occurring copper-binding tripeptide first isolated from human plasma in 1973. Present in blood, saliva, and urine, GHK-Cu levels decline significantly with age – from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60. This age-related decline has made it a subject of increasing research interest in the fields of longevity biology, dermatology, and tissue signaling.

This article provides a structured overview of the current research landscape surrounding GHK-Cu. All compounds on this site are supplied exclusively for controlled laboratory research (research use only).

What Is GHK-Cu?

GHK-Cu consists of the tripeptide Glycyl-L-Histidyl-L-Lysine bound to a copper(II) ion. Its unique molecular structure allows it to form stable complexes with copper, which plays a critical role in its bioactivity. The copper moiety acts as a cofactor for enzymes such as lysyl oxidase and superoxide dismutase, linking GHK-Cu activity to collagen crosslinking, antioxidant defense, and inflammatory regulation.

Researchers at the Broad Institute of MIT and Harvard analyzed GHK-Cu’s genome-wide effects using the Connectivity Map and found that GHK-Cu modulates the expression of 31.2% of human genes – upregulating 59% and downregulating 41% of affected genes. This broad genomic influence positions GHK-Cu as a highly versatile research compound.

Primary Research Domains

Collagen Synthesis & Skin Biology

GHK-Cu is among the most studied peptides in dermatological research. A randomized, double-blind clinical trial found that topical GHK-Cu (encapsulated in a nano-lipid carrier, applied twice daily for 8 weeks) reduced wrinkle volume by 55.8% compared to control serum, and by 31.6% compared to the commercially established peptide Matrixyl® 3000. Separately, a 2025 clinical study using a GHK-Cu gel demonstrated measurable increases in dermal collagen density via high-resolution ultrasound imaging over a 3-month period.

SIRT1 / STAT3 Pathway Modulation

Recent molecular studies (2024–2025) have identified SIRT1 (NAD-dependent deacetylase sirtuin-1) and STAT3 (signal transducer and activator of transcription 3) as primary intracellular targets of GHK-Cu activity. Research published in 2025 (Mao et al., PMID: 40672369) demonstrated that GHK-Cu upregulates SIRT1 expression while suppressing phosphorylated p-STAT3, promoting mucosal healing and enhancing tight junction protein expression in colitis models.

Wound Healing & Tissue Repair

Multiple animal studies have established wound-healing activity for GHK-Cu. In rabbit experimental wound models, GHK-Cu improved wound contraction, granular tissue formation, antioxidant enzyme activity, and blood vessel growth. GHK-Cu also functions as a matrikine – recruiting repair-associated cells and promoting angiogenesis, making it a subject of active research in tissue remodeling and extracellular matrix biology.

Anti-Inflammatory & Antioxidant Signaling

Laboratory models demonstrate that GHK-Cu exhibits anti-inflammatory and antioxidant actions, including inhibition of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and modulation of oxidative stress pathways via copper-mediated enzyme activity. GHK-Cu delivers copper in a redox-silent chelated form, potentially minimizing free-ion toxicity while restoring cupro-enzyme function.

Longevity & Neuroprotective Research

Emerging research investigates GHK-Cu in the context of aging biology and neurodegeneration. Gene expression analyses suggest GHK-Cu can reset gene expression patterns toward profiles associated with younger biological age. Laboratory models studying Alzheimer’s disease pathways represent a growing area of investigation.

Current Study Landscape (2026)

GHK-Cu benefits from a broader evidence base than many research peptides, including both preclinical and limited human trial data:

• Randomized double-blind trial (topical, n=controlled): Significant wrinkle volume reduction vs. Matrixyl® 3000 and control serum.
• 2025 collagen density study: Measurable dermal collagen increase documented via ultrasound after 3 months of topical application.
• 2025 colitis model (Mao et al.): GHK-Cu identified as novel SIRT1 activator with mucosal protective effects in DSS-induced colitis.

GHK-Cu holds no approved drug status as a systemic therapeutic in the EU or Germany. Topical cosmetic formulations containing GHK-Cu are legally available in many markets.

Evidence Grade at ISOLITE

Within the ISOLITE Peptides Research Hub, GHK-Cu is classified at ★★★★ Strong: supported by single RCTs, regional approvals in cosmetic applications, and a substantial body of preclinical plus limited human data.

→ View the full evidence overview in the ISOLITE Research Hub

Laboratory Handling & Reconstitution

GHK-Cu is typically supplied as a lyophilized powder. For laboratory use, it is reconstituted in sterile or bacteriostatic water. Use the ISOLITE Peptide Tools for precise concentration and dosing calculations:

→ Open the ISOLITE Peptide Tools Calculator

Legal Notice

GHK-Cu is not approved as a systemic medicinal product in Germany or the European Union. All ISOLITE products are intended exclusively for controlled in vitro laboratory research. Procurement is restricted to qualified researchers and licensed laboratory facilities.

References

• Mao et al. (2025), PMID: 40672369 – PubMed / MEDLINE
• Pickart & Margolina (2018): Regenerative and Protective Actions of the GHK-Cu Peptide – PMC6073405
• ISOLITE Research Hub

This article is for scientific information only. It does not constitute medical advice.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. First isolated by Croatian researchers in the 1990s as the bioactive fragment of a naturally occurring gastric protection protein, BPC-157 has become one of the most studied peptides in preclinical science – particularly across gastrointestinal biology, tissue signaling, and cellular regeneration pathways.

This article provides a structured, evidence-based overview of the current research landscape surrounding BPC-157. All compounds on this site are supplied exclusively for controlled laboratory research (research use only).

What Is BPC-157?

BPC-157 is a pentadecapeptide with the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (CAS No. 137525-51-0). The molecule was characterized as the bioactive fragment of Body Protection Compound (BPC), a protein naturally present in trace amounts in human gastric juice.

One of its most notable properties is exceptional chemical stability: BPC-157 remains intact in gastric fluid for over 24 hours, while most peptides are hydrolyzed within minutes (Sikiric et al., 2011). This makes it a particularly useful reference compound in laboratory models studying peptide behavior under physiological conditions.

Primary Research Domains

Gastrointestinal Signaling

The gastrointestinal tract represents the best-documented research area for BPC-157. Early comparative studies in preclinical ulcer models demonstrated consistent activity across the entire GI tract – from esophagus and stomach through intestine, liver, and pancreas. BPC-157 was subsequently designated as PL-14736 for IBD-related clinical research programs, underscoring its translational relevance.

Tissue Structure & Cell Signaling

Multiple laboratory studies examine how BPC-157 interacts with fibroblasts, collagen synthesis, and cell migration pathways. A systematic review covering 36 studies (1993–2024) summarized preclinical findings in the orthopedic and sports medicine context, noting consistently positive structural outcomes in musculoskeletal injury models.

Vascular & Inflammatory Mechanisms

Research focuses on BPC-157’s modulation of the nitric oxide system (NO synthase), inhibition of pro-inflammatory cytokines, and promotion of angiogenesis – all central to ongoing cytoprotective laboratory investigations.

Neuroprotective Research

More recent laboratory models explore potential neuroprotective properties of BPC-157, including effects on peripheral nerve injury models and interactions within dopaminergic signaling pathways.

Current Study Landscape (2026)

The large majority of available data derives from preclinical animal and cell models. Large-scale randomized controlled human trials remain outstanding.

• 2021 – Knee pain pilot (n=16): 87.5% reported symptom improvement after 6–12 months. No control group; evidence quality limited.
• 2024 – Interstitial cystitis study (n=12): 80–100% symptom reduction reported. No control arm.
• 2025 – IV safety study (n=2): Tolerability documented up to 20 mg IV. Too small for efficacy conclusions.

BPC-157 holds no approved drug status in the EU or Germany.

Evidence Grade at ISOLITE

Within the ISOLITE Peptides Research Hub, BPC-157 is classified at ★★★ Moderate: predominantly preclinical data, small human case series, no randomized controlled human trials currently available.

→ View the full evidence overview in the ISOLITE Research Hub

Laboratory Handling & Reconstitution

BPC-157 is typically supplied as a lyophilized powder and reconstituted with Bacteriostatic Water (BAC Water) for laboratory use. Use the ISOLITE Peptide Tools for precise concentration and dosing calculations:

→ Open the ISOLITE Peptide Tools Calculator

Legal Notice

BPC-157 is not approved as a medicinal product in Germany or the European Union. All ISOLITE products are intended exclusively for controlled in vitro laboratory research. Procurement is restricted to qualified researchers and licensed laboratory facilities.

References

• Sikiric et al. (2011) – PubMed / MEDLINE
• ClinicalTrials.gov – Search: PL-14736
• ISOLITE Research Hub

This article is for scientific information only. It does not constitute medical advice.